长城

China's pharmaceutical industry sees accelerated innovation breakthroughs in H1_我的网站

一 |     (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed.    China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval.    A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country.    Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category.    This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading.     At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly.    To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong.    The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions.    In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total.        (By Tang Yuxian)                    。

二 |     近日，在杭州下沙港，工作人员轻点鼠标，最后一票出口集装箱的出港信息录入系统，屏幕上的状态栏跳转为“放行”——杭州下沙港海关监管作业场所首票测试单顺利完成。这意味着，杭州首个千吨级内河港口正式具备外贸货物进出口通关作业能力。“从出口申报、查验到放行，整套流程跑下来非常顺畅。”钱江海关驻下沙办事处副主任潘鹏介绍，下沙港海关监管作业场所通过杭州海关审核验收后，已完成多轮全流程测试，目前各项准备工作已经就绪，即将正式运行。过去，杭州企业做外贸出口，货物往往要绕道外地口岸办理通关手续。现在，在下沙港就能“一站式”完成申报、查验、放行全流程，实现在“家门口通关”。

三 | 地理距离缩短了，物流周转更快了，中间转运仓储的成本也省下来了。下沙港位于钱塘区京杭运河二通道东岸，是杭州最靠近主城区的水上综合作业区，业务辐射杭州全域及湖州、嘉兴、绍兴、义乌等周边区域。依托京杭运河二通道通江达海的独特区位优势，下沙港可以通过“海河联运”模式，连接宁波舟山港、嘉兴乍浦港等国际航运枢纽，为杭州外贸企业打通一条便捷的新通道。

Current article:http://www.bainangmieruopanglaomen.sbs/teg/xmy84.doc

Published on:18:46:48